knowledge -WSS

knowledge

author：Wikipedia 2025-10-02 20:49:56 - browse：83

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Pharma patents targeted by Biden in move to slash drug prices

WSS

Radiology is caught between AI's potential and concern for patients

Patients' immediate access to test results puts radiologists in a bind

Cognito secures funding to test medical device for Alzheimer's

FDA drug safety: Singulair case shows systemic surveillance flaws

Pregnancy discrimination could be enabled by AI

Leukemia patients are helped by Syndax's new type of therapy

Wikipedia

knowledge

Wikipedia

ChatGPT in medicine: STAT answers readers' burning questions

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Medical records are filled with copy

SCOTUS to consider access to abortion pill mifepristone

State Dept. review finds Biden bears some blame for Afghanistan failures

Pfizer plans to depart BIO

Dobbs anniversary: the lost opportunity of abortion as health care

Pfizer plans to depart BIO

New air purifier tech could be key to improving indoor air quality

Chemotherapy shortages won’t get better under Biden’s latest plan

explore

Pregnancy discrimination could be enabled by AI

SAMSHA loosens regulations on methadone treatment centers

Pregnancy discrimination could be enabled by AI

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Cybersecurity threat forces Lurie Children's to take systems offline

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Wikipedia

focus

knowledge

hotspot